Risk Intelligence
Core Model
—
Not Available
Fundamentally Qualified
How strong and defensively sound is the company?
This reading is not available for this company yet.
Suggestions
GILD · Nasdaq
GILEAD SCIENCES, INC.
Private betaHealth Care · Biotechnology
$143.72
-0.75%
Close on Sep 11, 2026
Defensively Qualified
Updated 6/30/2026
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Investment Report Card
GILEAD SCIENCES, INC.
Health Care · Biotechnology · Data confidence partial
No Pro Investor Score today
Risk Intelligence is unavailable
Long-Term Potential
Research Model
—
Not Available
Ordinary Compounder
Does the business have the characteristics needed to create value over many years?
This reading is not available for this company yet.
Fundamental Momentum
Research Model
—
Not Available
Accelerating
Is the underlying business getting stronger or weaker?
This reading is not available for this company yet.
Ownership Intelligence
Supplemental Intelligence
—
Not Available
Positive disclosed activity
What are important owners actually doing?
This reading is not available for this company yet.
Valuation Intelligence
Research Model
D
50 / 100
Reasonable
Is today's price reasonable?
Weaker than most covered companies on this measure — and valuation is researched separately from the Suggested Investment Score.
Capital Returns Intelligence
Research Model
C+
65 / 100
Favorable Capital Returns
How effectively does the company reward shareholders?
Around the middle of the covered universe — and capital returns are researched separately from the Suggested Investment Score.
Why it stands out
- Business Quality meets the frozen IA Defensive qualification.
- More disclosed holders are new or increasing than reducing or exiting.
What holds it back
No weakening evidence is recorded in today's readings.
Long-term view
Long-Term Potential is not available for this company, so no long-term reading is shown.
Ownership view
No disclosed ownership reading is available at the required confidence, so ownership is left blank rather than estimated.
Valuation view
GILEAD SCIENCES, INC. reads 50 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
Capital returns view
GILEAD SCIENCES, INC. reads 65 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend that has grown about 9.4% a year. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
What changed
No meaningful recorded changes in the stored history.
Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.
Compare GILD with other companiesResearch Collections
This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.
Browse collections60-Second Brief
Too few stored readings exist for this company to summarise honestly.
Composite discovery model
Pro Investor Score
Pro Investor Score™
Not currently in the Suggested Investment ranking
Risk Intelligence is unavailable. A composite score is only published when every required input is available for this company. Nothing is estimated to fill a gap, and exclusion from the ranking is not a sell instruction.
COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Ranking updated September 12, 2026
Researched separately
Valuation Intelligence 50 · Reasonable
RESEARCH MODEL
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
Researched separately
Capital Returns Intelligence 65 · Favorable Capital Returns
RESEARCH MODEL
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
Why this company scores the way it does
This company does not currently hold a stored Pro Investor Score, so no contribution breakdown can be shown.
Pro Investor Intelligence™
Reported by insiders, large shareholders and professional funds. Shown beside our research, never blended into it.
Loading professional-investor activity…
Stored snapshots only
What changed
Research-score history available since September 2026.
Stored research history does not yet cover a full 30 days comparison for this company.
A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.
Learn the metrics on this page
Plain-English definitions, with the formula and the limitations of each measure.
Fifth research lens · outside the score
Valuation Intelligence
Valuation Intelligence
Is today's price reasonable?
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
50/ 100
Reasonable
RESEARCH MODEL
Excellent coverage
Compared with its history
6
Expensive
Is this company expensive or inexpensive compared with its own history?
Compared with peers
47
Elevated
How expensive is this stock compared with similar companies?
Earnings & cash flow
72
Attractive
How much financial output does an investor receive relative to the price paid?
Growth-adjusted
92
Very Attractive
Does the company's growth help justify the valuation investors are paying?
GILEAD SCIENCES, INC. reads 50 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Valuation history
Stored readings only. The dashed line is this company's own median for the selected measure.
Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.
Current EV/EBITDA 111.6x · own median 11.4x · peer median 20.2x
Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.
Sixth research lens · outside the score
Capital Returns Intelligence
Capital Returns Intelligence
How effectively does the company reward shareholders?
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
65/ 100
Favorable Capital Returns
RESEARCH MODEL
Excellent coverage
Dividend Quality
90
Exceptional Capital Returns
Dividend reliability
Buyback Effectiveness
42
Moderate Capital Returns
Do buybacks actually reduce shares?
The company spends on share repurchases, but much of that activity offsets share issuance rather than materially reducing the share count.
Dilution Control
46
Moderate Capital Returns
Is your ownership share protected?
Capital Return Sustainability
88
Exceptional Capital Returns
Can the cash flow support it?
Shareholder Yield
56
Moderate Capital Returns
Cash returned versus company value
GILEAD SCIENCES, INC. reads 65 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend that has grown about 9.4% a year.
This company spent cash repurchasing stock, but the share count did not fall meaningfully because it also issued shares. Repurchase spending alone did not increase existing shareholders' ownership.
How returned cash was used
Dividends $4.07B · net repurchases $1.14B · total returned $5.20B · 40% of free cash flow
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Capital returns history
Stored readings only. History builds forward from activation rather than being reconstructed.
Only one stored reading exists for this measure so far, so there is nothing to chart yet.
Why higher yield isn't always better
A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.
Why buybacks can be misleading
Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.
What these terms mean
- Dividend Yield
- The annual dividend relative to the current share price.
- Payout Ratio
- The share of company earnings used to pay dividends.
- Free Cash Flow Payout
- How much of the company's available cash is being used for dividends.
- Share Repurchases
- When a company buys back its own stock.
- Dilution
- When the number of shares increases, reducing each existing share's percentage ownership of the company.
- Shareholder Yield
- A combined view of dividends and net share repurchases relative to the company's market value.
Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Pro Investor Score.
Stored daily snapshots only
Ranking history
| Today | Not ranked | No stored score |
|---|---|---|
| 30 days ago | Not ranked | No stored score |
| 90 days ago | Not ranked | No stored score |
| First suggested | Not yet suggested | |
| Highest rank | Not ranked | |
In the company’s own words
What this company does
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as "Gilead," the "company," "we," "our" or "us") is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.
We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Our innovative medicines represent advancements by offering first-in-class therapies, greater efficacy, enhanced modes of delivery, more convenient treatment and prevention regimens, improved resistance profiles and reduced side effects.
In 2025, our commercial portfolio included more than 25 therapies, including the following products and collaboration products with approved indications in the U.S.:
Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Biktarvy is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, bictegravir, emtricitabine ("FTC") and tenofovir alafenamide ("TAF").
Quoted from the business section of this company’s 10-K filed February 24, 2026. Read the filing
Four distinct intelligence areas
The IA view
Risk Intelligence
Production core
47
Restricted
-8.5 vs Jun 30, 2026
Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.
As of Sep 11, 2026
Long-Term Potential
Research model
52
Mid range
-3.9 vs Mar 31, 2026
Durable business economics and reinvestment characteristics. Independent external validation is pending.
As of Jun 30, 2026
Fundamental Momentum
Research model
65
Mid range
+7.9 vs Mar 31, 2026
Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.
As of Jun 30, 2026
Elite Investor Activity
Supplemental
20
Bottom range
0 vs Jun 30, 2026
Only 5 tracked managers disclosed a position — treat as limited coverage.
As of Sep 11, 2026
Company intelligence
GILD score history
Each area is measured and reported separately. No combined score exists.
GILD intelligence history from 2023-09-30 to 2026-09-11. Risk Intelligence 46.9 on 2026-09-11, down 8.5 from 55.4 on 2026-06-30. Long-Term Potential 52 on 2026-06-30, down 3.9 from 55.9 on 2026-03-31. Fundamental Momentum 65 on 2026-06-30, up 7.9 from 57.1 on 2026-03-31. Elite Investor Activity 20 on 2026-09-11, unchanged 0 from 20 on 2026-06-30. Each area is reported separately and is never combined into a single score.
Risk Intelligence 46.9 as of Sep 11, 2026 (-8.5 vs prior period) · Production core
Long-Term Potential 52 as of Jun 30, 2026 (-3.9 vs prior period) · Research model
Fundamental Momentum 65 as of Jun 30, 2026 (+7.9 vs prior period) · Research model
Elite Investor Activity 20 as of Sep 11, 2026 (0 vs prior period) · Supplemental
Share price
GILD price history
Closing prices adjusted for splits and dividends. Past prices do not indicate future results.
- 6M change
- +0.2%
- 1Y change
- +25.1%
- 3Y change
- +105.1%
- 5Y change
- +139.3%
- Max change
- +181.3%
Last stored close $143.72 · +25.1% over the selected range · 52 sessions shown
Balanced evidence
Why IA likes it
- Business Quality meets the frozen IA Defensive qualification.
- More disclosed holders are new or increasing than reducing or exiting.
Risk and uncertainty
What IA doesn’t like
- No specific negative evidence is available. This is not evidence of low risk.
What would change our view
- Business Quality falling below the frozen qualification threshold.
- Price Risk moving to a less favorable category.
- A sustained reversal in the Fundamental Momentum research evidence.
- New material public ownership disclosures.
Public filings · descriptive only
Elite Investor Activity
Reporting holders
39
New holders
26
Increasing
6
Reducing
4
Exiting
2
Coverage
Excellent
Positive disclosed activity · Report period 2023-09-30 · Public 12/27/2023
| Manager | Change | Portfolio weight | Rank | Disclosed |
|---|
Insufficient high-confidence manager coverage.
Objective stored changes
What changed
- Risk Intelligence
IA Defensive weakened
Business Quality qualification score moved from 55.4 to 36.6.
- Long-Term Potential
IA Compounder softened
IA Compounder research score moved from 55.9 to 52.0.
- Fundamental Momentum
Fundamental Momentum improved
Fundamental Momentum research score moved from 57.1 to 65.0.
- Elite Investor Activity
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 60 to 20 for the reporting period ending 2026-06-30.
- Elite Investor Activity
Elite Investor Consensus strengthened
Disclosed agreement among tracked managers moved from 33 to 60 for the reporting period ending 2025-12-31.
- Elite Investor Activity
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 92 to 33 for the reporting period ending 2025-09-30.
- Elite Investor Activity
Elite Investor Consensus strengthened
Disclosed agreement among tracked managers moved from 60 to 92 for the reporting period ending 2025-06-30.
- Elite Investor Activity
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 100 to 60 for the reporting period ending 2025-03-31.
- Elite Investor Activity
Tracked managers initiated positions
3 tracked managers first disclosed a position for the reporting period ending 2024-09-30.
Ownership timeline
No high-confidence public ownership events are available.
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.